Plasma exosome protein marker for early screening of nasopharynx cancer and application of plasma exosome protein marker

A nasopharyngeal carcinoma marker technology, applied in the field of plasma exosome protein markers, can solve the problems that there are no nasopharyngeal carcinoma exosome protein markers and molecular classifiers

Pending Publication Date: 2021-06-04
李欣
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there are no reports on exosomal protein markers and molecular classifiers derived from the microenvironment of nasopharyngeal carcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasma exosome protein marker for early screening of nasopharynx cancer and application of plasma exosome protein marker
  • Plasma exosome protein marker for early screening of nasopharynx cancer and application of plasma exosome protein marker
  • Plasma exosome protein marker for early screening of nasopharynx cancer and application of plasma exosome protein marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Screening and Identification of Example 1 Protein

[0051] Select 10 cases of early nasopharyngeal carcinoma (E-NPC) and 10 healthy people (NC) plasma samples, match them according to age and sex, and use non-standard quantitative technology and quantitative proteomics technology based on mass spectrometry to organically combine after separating proteins in serum. Quantitative proteome research on samples ( figure 1 ).

[0052] In the present invention, the inventors have identified 1431 proteins in total, of which 612 can be quantified ( figure 2 ). Taking 1.5 times as the threshold for differential expression changes, and using the statistical test t-test p-value image 3 , Figure 4 ).

[0053] Protein quantitative repeatability was assessed by principal component analysis (PCA) and relative standard deviation (RSD) statistical analysis methods. PCA showed a good degree of clustering among replicate samples, indicating good quantitative replication ( Figure 5 ...

Embodiment 2

[0056] Example 2 Quantitative Proteomics Analysis (PRM)

[0057] EPB41 (P11171), SELP (P16109), ANK1 (P16157), CA1 (P00915), BLVRB (P30043), SPTA1 (P02549), SPTB (P11277), PKM ( ( P50552) expression difference in 15 NC and 10 E-NPC samples.

[0058] The results showed that the ROC curve AUC values ​​of CA1, EPB41, ANK1, SPTA1, BLVRB, SELP to distinguish NC and E-NPC were 0.9333, 0.87, 0.8267, 0.8467, 0.8633, 0.75 ( Figure 7 ), indicating that this marker can better distinguish NC from E-NPC. A total of 6 proteins including CA1, EPB41, ANK1, SPTA1, BLVRB, and SELP had significant differences in expression, as shown in the box plot of relative protein expression levels ( Figure 8 ) and relative expression level heatmap ( Figure 9 ), it can be used as a protein marker of E-NPC. The combination of CA1, EPB41, ANK1, SPTA1, BLVRB, and SELP has good sensitivity and specificity in distinguishing NC and E-NPC, and the ROC curve AUC is 0.8516 ( Figure 10 A). The combination o...

Embodiment 3

[0060] Embodiment 3 clinical case

[0061] In clinical practice, NC and E-NPC patients are randomly selected for verification testing, and 5 cases of each of NC and E-NPC patients are selected below to demonstrate the actual effect of the present invention.

[0062] Healthy person Huang Moumou, female, 47 years old, the relative abundance of proteins verified by PRM is: CA1 (0.07), EPB41 (0.12), ANK1 (0.06), SPTA1 (0.13), BLVRB (0.13), SELP (0.09);

[0063] Healthy person, male, 62 years old, the relative abundance of proteins verified by PRM is: CA1 (0.07), EPB41 (0.14), ANK1 (0.05), SPTA1 (0.11), BLVRB (0.10), SELP (0.06) ;

[0064] Healthy person, male, 47 years old, the relative abundance of proteins verified by PRM is: CA1 (0.13), EPB41 (0.13), ANK1 (0.12), SPTA1 (0.14), BLVRB (0.30), SELP (0.35) ;

[0065] Healthy person, male, 48 years old, the relative abundance of proteins verified by PRM is: CA1 (0.19), EPB41 (0.07), ANK1 (0.12), SPTA1 (0.14), BLVRB (0.05), SELP ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a plasma exosome protein marker for early screening of nasopharynx cancer and application of the plasma exosome protein marker. Six early specific proteins (plasma exosomes CA1, EPB41, ANK1, SPTA1, BLVRB and SELP) related to nasopharynx cancer and a molecular classifier formed by the six early specific proteins are screened and further identified, and the absolute protein expression quantity and relative abundance of the proteins are analyzed to realize early identification of nasopharynx cancer. The plasma exosome protein marker can be applied to development of a series of detection technologies or detection kits related to nasopharyngeal carcinoma such as ELISA, chemiluminiscence, protein chips and the like, and can be applied to early screening and discovery of clinical nasopharyngeal carcinoma patients.

Description

technical field [0001] The invention relates to the field of molecular markers, in particular to a plasma exosome protein marker for early screening of nasopharyngeal carcinoma and its application. Background technique [0002] Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from nasopharyngeal epithelial cells. It occurs frequently in Guangdong and Guangxi regions, and its onset is insidious. Most patients have lymph node metastasis when they are diagnosed. Although radiotherapy and chemotherapy are the first choice for the treatment of nasopharyngeal carcinoma, as the time of discovery lags behind, for patients with metastases at the time of diagnosis, this treatment method still has the problems of high treatment failure rate, high recurrence rate and high mortality. Therefore, the discovery of early-stage specific molecular markers for NPC will help in the early detection of NPC patients, so as to detect NPC in occult stage as early as possible before met...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68G01N33/573
CPCG01N33/57407G01N33/57484G01N33/68G01N33/573G01N2333/47G01N2333/988G01N2333/90206
Inventor 李欣丁腾腾彭曼莉
Owner 李欣
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap